ZEBRHA 2 Study

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

ZEBHRA 2 is a Phase 3 randomized clinical trial being conducted to evaluate the efficacy and safety of NXT007 prophylaxis compared with emicizumab prophylaxis in male and female participants, age 12 years and older, with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.

Individuals with mild hemophilia A with inhibitors may be eligible to participate if they have documented FVIII inhibitors resulting in chronic (≥12 months) reduction of endogenous FVIII levels to <5 IU/dL. The study will also evaluate the pharmacodynamics and pharmacokinetics of NXT007 treatment in individuals with hemophilia A.

NXT007 is an investigational, next-generation, bispecific monoclonal antibody designed to replace the co-factor function of missing or deficient activated FVIII by bridging activated FIX and FX. NXT007 aims to normalize hemostasis in people with hemophilia A.

To learn more about the ZEBRHA 2 study:

• For participating sites and patient referrals, please click on the Clinicaltrials.gov link:
  ZEBRHA 2 (NCT07416604)
   
• Contact Genentech Trial Information Support (888) 662-6728
  (Monday - Friday, 5am - 5pm PT)

Sponsored By: